Patient baseline characteristics
| . | IXZ, n = 39 (53%) . | Control, n = 34 (57%) . | P value . |
|---|---|---|---|
| Age, y, median (range) | 52.2 (29-69) | 54.9 (20-69) | .89 |
| Sex, male/female, n (%) | 24 (61.5)/15 (38.5) | 17 (50)/17 (50) | .32 |
| Diagnosis, n (%) | .87 | ||
| Lymphoma | 8 (20.5) | 6 (17.6) | |
| AML | 14 (35.9) | 14 (41.2) | |
| ALL | 2 (5.1) | 2 (5.9) | |
| Myelodysplastic syndrome | 11 (28.2) | 7 (20.6) | |
| Multiple myeloma | 4 (10.3) | 4 (11.8) | |
| CMPD | 0 | 1 (2.9) | |
| Donor, n (%) | .96 | ||
| MRD | 29 (74.4) | 18 (52.9) | |
| MURD | 9 (23.1) | 14 (41.3) | |
| MMRD | 1 (2.6) | 0 | |
| MMURD | 0 | 2 (5.9) | |
| GVHD prophylaxis, n (%) | .46 | ||
| Tk-MTX | 9 (23.1) | 5 (14.7) | |
| Tk/CsA-siro | 6 (20.5) | 11 (32.3) | |
| Tk-siro-MMF | 22 (56.4) | 18 (52.9) | |
| Conditioning, n (%) | .61 | ||
| Myeloablative | 10 (25.6) | 7 (20.6) | |
| Reduced intensity | 29 (74.4) | 27 (79.4) | |
| Previous aGVHD, n (%) | .37 | ||
| Yes | 34 (86.8) | 27 (78.8) | |
| No | 5 (13.2) | 7 (21.2) |
| . | IXZ, n = 39 (53%) . | Control, n = 34 (57%) . | P value . |
|---|---|---|---|
| Age, y, median (range) | 52.2 (29-69) | 54.9 (20-69) | .89 |
| Sex, male/female, n (%) | 24 (61.5)/15 (38.5) | 17 (50)/17 (50) | .32 |
| Diagnosis, n (%) | .87 | ||
| Lymphoma | 8 (20.5) | 6 (17.6) | |
| AML | 14 (35.9) | 14 (41.2) | |
| ALL | 2 (5.1) | 2 (5.9) | |
| Myelodysplastic syndrome | 11 (28.2) | 7 (20.6) | |
| Multiple myeloma | 4 (10.3) | 4 (11.8) | |
| CMPD | 0 | 1 (2.9) | |
| Donor, n (%) | .96 | ||
| MRD | 29 (74.4) | 18 (52.9) | |
| MURD | 9 (23.1) | 14 (41.3) | |
| MMRD | 1 (2.6) | 0 | |
| MMURD | 0 | 2 (5.9) | |
| GVHD prophylaxis, n (%) | .46 | ||
| Tk-MTX | 9 (23.1) | 5 (14.7) | |
| Tk/CsA-siro | 6 (20.5) | 11 (32.3) | |
| Tk-siro-MMF | 22 (56.4) | 18 (52.9) | |
| Conditioning, n (%) | .61 | ||
| Myeloablative | 10 (25.6) | 7 (20.6) | |
| Reduced intensity | 29 (74.4) | 27 (79.4) | |
| Previous aGVHD, n (%) | .37 | ||
| Yes | 34 (86.8) | 27 (78.8) | |
| No | 5 (13.2) | 7 (21.2) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CMPD, chronic myeloproliferative disease; MMRD, mismatched related donor; MMURD, mismatched unrelated donor; MRD, matched related donor; MURD, matched unrelated donor; Tk/CsA-siro, tacrolimus/cyclosporine-sirolimus; Tk-MTX, tacrolimus-methotrexate; Tk-siro-MMF, tacrolimus-sirolimus-mycophenolate mofetil.